Literature DB >> 23801336

Virus NAT for HIV, HBV, and HCV in Post-Mortal Blood Specimens over 48 h after Death of Infected Patients - First Results.

Thomas Meyer1, Susanne Polywka, Birgit Wulff, Carolin Edler, Ann Sophie Schröder, Ina Wilkemeyer, Ulrich Kalus, Axel Pruss.   

Abstract

OBJECTIVE: According to EU regulations (EU directive 2006/17/EC), blood specimens for virologic testing in the context of post-mortal tissue donation must be taken not later than 24 h post mortem.
METHODS: To verify validity of NAT in blood specimens collected later, viral nucleic acid concentrations were monitored in blood samples of deceased persons infected with HIV (n = 7), HBV (n = 5), and HCV (n = 17) taken upon admission and at 12 h, 24 h, 36 h and 48 h post mortem. HIV and HCV RNA were quantified using Cobas TaqMan (Roche), HBV DNA was measured by in-house PCR.
RESULTS: A more than 10-fold decrease of viral load in samples taken 36 h or 48 h post mortem was seen in one HIV-infected patient only. For all other patients tested the decrease of viral load in 36-hour or 48-hour post-mortal samples was less pronounced. Specimens of 3 HIV- and 2 HBV-infected patients taken 24 h post mortem or later were even found to have increased concentrations (>10-fold), possibly due to post-mortem liberation of virus from particular cells or tissues.
CONCLUSION: Our preliminary data indicate that the time point of blood collection for HIV, HBV and HCV testing by PCR may be extended to 36 h or even 48 h post mortem and thus improve availability of tissue donations.

Entities:  

Keywords:  Post-mortal tissue donation; Virus safety NAT screening

Year:  2012        PMID: 23801336      PMCID: PMC3678255          DOI: 10.1159/000345610

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  18 in total

Review 1.  Assessing the impact of HBV NAT on window period reduction and residual risk.

Authors:  Steven H Kleinman; Michael P Busch
Journal:  J Clin Virol       Date:  2006-05       Impact factor: 3.168

2.  Serological viral testing of cadaveric cornea donors.

Authors:  Dominique Challine; Françoise Roudot-Thoraval; Patrick Sabatier; Fabienne Dubernet; Patrick Larderie; Pierrette Rigot; Jean-Michel Pawlotsky
Journal:  Transplantation       Date:  2006-09-27       Impact factor: 4.939

Review 3.  High infectious risk donors: what are the risks and when are they too high?

Authors:  Lauren M Kucirka; Andrew L Singer; Dorry L Segev
Journal:  Curr Opin Organ Transplant       Date:  2011-04       Impact factor: 2.640

4.  Polymerase chain reaction in cadaveric blood and tissues.

Authors:  G Burtonboy; C Delloye
Journal:  Transplant Proc       Date:  1996-10       Impact factor: 1.066

5.  Evaluation of serological screening of cadaveric sera for donor selection for cornea transplantation.

Authors:  A Heim; D Wagner; T Rothämel; U Hartmann; J Flik; W Verhagen
Journal:  J Med Virol       Date:  1999-07       Impact factor: 2.327

6.  A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.

Authors:  Michael P Busch; Simone A Glynn; Susan L Stramer; D Michael Strong; Sally Caglioti; David J Wright; Brandee Pappalardo; Steven H Kleinman
Journal:  Transfusion       Date:  2005-02       Impact factor: 3.157

Review 7.  Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.

Authors:  L M Kucirka; H Sarathy; P Govindan; J H Wolf; T A Ellison; L J Hart; R A Montgomery; R L Ros; D L Segev
Journal:  Am J Transplant       Date:  2011-03-14       Impact factor: 8.086

8.  Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor.

Authors:  Barna D Tugwell; Priti R Patel; Ian T Williams; Katrina Hedberg; Feng Chai; Omana V Nainan; Ann R Thomas; Judith E Woll; Beth P Bell; Paul R Cieslak
Journal:  Ann Intern Med       Date:  2005-11-01       Impact factor: 25.391

9.  Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.

Authors:  C Micha Nübling; Uwe Unkelbach; Michael Chudy; Rainer Seitz
Journal:  Transfusion       Date:  2008-01-15       Impact factor: 3.157

10.  Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor.

Authors:  R J Simonds; S D Holmberg; R L Hurwitz; T R Coleman; S Bottenfield; L J Conley; S H Kohlenberg; K G Castro; B A Dahan; C A Schable
Journal:  N Engl J Med       Date:  1992-03-12       Impact factor: 91.245

View more
  6 in total

1.  Validation of Virus NAT for HIV, HCV, HBV and HAV Using Post-Mortal Blood Samples.

Authors:  Knut Gubbe; Yvonne Scharnagl; Steffi Grosch; Torsten Tonn; Michael Schmidt; Kai M Hourfar; Andreas Karl; Erhard Seifried; Ina Wilkemeyer; Ulrich Kalus
Journal:  Transfus Med Hemother       Date:  2012-11-13       Impact factor: 3.747

2.  Current trends in tissue banking.

Authors:  Axel Pruss; Ulrich Kalus
Journal:  Transfus Med Hemother       Date:  2012-12       Impact factor: 3.747

3.  Validation of Spiked Postmortem Blood Samples from Cornea Donors on the Abbott ARCHITECT and m2000 Systems for Viral Infections.

Authors:  Ingo Schmack; Seda Ballikaya; Brigitte Erber; Irina Voehringer; Ulrich Burkhardt; Gerd U Auffarth; Paul Schnitzler
Journal:  Transfus Med Hemother       Date:  2019-09-24       Impact factor: 3.747

4.  Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus.

Authors:  Axel Pruß; Akila Chandrasekar; Jacinto Sánchez-Ibáñez; Sophie Lucas-Samuel; Ulrich Kalus; Holger F Rabenau
Journal:  Transfus Med Hemother       Date:  2020-12-22       Impact factor: 3.747

5.  How safe is safe, and where are we in the journey toward safest of safe?

Authors:  Lalit Dar; Radhika Tandon
Journal:  Indian J Ophthalmol       Date:  2017-11       Impact factor: 1.848

6.  Mortuary and hospital-based HIV mortality surveillance among decedents in a low-resource setting: lessons from Western Kenya.

Authors:  Emmanuel Nyakeriga; Wanjiru Waruiru; Valarie Opollo; Anthony Waruru; Leonard Kingwara; Dickens Onyango; Muthoni Junghae; Sheru Muuo; Teresia Macharia; Catherine Ngugi; Mary Mwangome; Hammad Ali
Journal:  BMC Public Health       Date:  2022-03-29       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.